DOWNSTREAM PROCESSING FEATURED ARTICLES
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark Office (USPTO) has granted the first patent covering the Company's latest antibody platform Ylanthia, which became commercially available for existing and new partners in 2012.
-
Genetic Immunity Receives GMP Certification For In-House Manufacturing Facility
Genetic Immunity (OTCBB: PWRV) is pleased to announce the GMP approval of its manufacturing facility. The development of the GMP manufacturing process and the facility was financed from a $4 million grant received from the Hungarian Office for Innovation and Technology.
-
Galapagos Announces GSK2586184 JAK1 Molecule Progresses To Phase 2 Studies
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
-
Avid Bioservices Announces Completion Of Facility Upgrades In Response To Increased Demand For Its Contract Manufacturing Services
Avid Bioservices, Inc, a contract manufacturing organization (CMO) focused on the process development and manufacturing of monoclonal antibodies, proteins and enzymes, today announced that its demand for services has reached an all-time high, while projected revenue for its current fiscal year ending April 2013 is expected to surpass $18 million, a 20% increase from the previous fiscal year.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
![A Purification Strategy For Clinical-Grade Monoclonal Antibody]( "A Purification Strategy For Clinical-Grade Monoclonal Antibody")
A Purification Strategy For Clinical-Grade Monoclonal AntibodymAbs are currently the most important class of therapeutic proteins. Advances in upstream process technologies have led to tremendous improvement of mAb titers in mammalian cell culture.
-
Rapid Chemically-Defined Feed Media Development to Improve Simulated Cell Culture Processes
Implementing an optimized feed medium may be the most effective alternative for modifications to the growth medium in an existing process.
-
Met One Sensors Resistant To Vaporous Hydrogen Peroxide (VHP) Pharmaceutical manufacturers often require an aseptic production environment to minimize the presence of microbes and their potential contamination of the manufactured product.
-
Agilent Microarray Grant Application Support White Paper This guide offers an overview of Agilent’s microarray and SureSelect product offerings with ordering details to assist researchers with the details of grant submission.
-
Compound Profiling And Toxicity
Utilizing a systems approach to drug discovery has generated a multitude of high affinity compounds for various classes of molecular targets with different degrees of disease state validation.
-
USP <787> Small Volume Testing With Liquid Particle Counters
By their very nature, biological therapeutics are not only expensive to manufacture but are often produced in small volumes.
DOWNSTREAM PROCESSING PRODUCTS
CHT is a leading purification medium of biomolecules in today’s demanding downstream process industry. Its mixed-mode support offers unique selectivities and often separates biomolecules that appear homogeneous with other chromatographic methods. The diverse binding capabilities of CHT for host cell proteins, leached protein A, antibody dimers and aggregates, nucleic acids, and viruses allow its use at any stage from initial capture to final polishing.
Amsphere™ A3 is a next generation Protein A chromatography resin for advanced protein separation in downstream processing of therapeutic antibodies manufacturing. With high capacity resin, Amsphere™ A3 has an overall improved process robustness, flow characteristics, optimized impurity removal, productivity and resin lifetime.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.